Coya Therapeutics' (COYA) "Buy" Rating Reaffirmed at Chardan Capital

Chardan Capital reissued their buy rating on shares of Coya Therapeutics (NASDAQ:COYA - Free Report) in a research report report published on Wednesday, Benzinga reports. Chardan Capital currently has a $14.00 price objective on the stock.

Separately, HC Wainwright began coverage on shares of Coya Therapeutics in a research report on Monday, September 16th. They set a "buy" rating and a $18.00 price objective for the company.

Coya Therapeutics Stock Down 9.7 %

Shares of NASDAQ:COYA traded down $0.71 during midday trading on Wednesday, hitting $6.66. The stock had a trading volume of 256,715 shares, compared to its average volume of 70,763. Coya Therapeutics has a 12 month low of $4.40 and a 12 month high of $10.69. The business's 50-day simple moving average is $6.87 and its 200-day simple moving average is $7.09. The company has a market cap of $97.28 million, a P/E ratio of -7.83 and a beta of 0.58.

Coya Therapeutics (NASDAQ:COYA - Get Free Report) last released its earnings results on Monday, August 12th. The company reported ($0.19) earnings per share for the quarter. The company had revenue of $3.43 million for the quarter. As a group, equities analysts predict that Coya Therapeutics will post -1.27 earnings per share for the current year.

Institutional Investors Weigh In On Coya Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of COYA. Vanguard Group Inc. increased its stake in shares of Coya Therapeutics by 772.3% in the first quarter. Vanguard Group Inc. now owns 847,490 shares of the company's stock valued at $8,407,000 after buying an additional 750,338 shares during the period. Renaissance Technologies LLC acquired a new position in shares of Coya Therapeutics in the second quarter valued at approximately $101,000. GHP Investment Advisors Inc. acquired a new position in shares of Coya Therapeutics in the third quarter valued at approximately $169,000. Finally, Gilbert & Cook Inc. acquired a new stake in Coya Therapeutics during the 2nd quarter valued at approximately $61,000. Institutional investors own 39.75% of the company's stock.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.